Upholding of WARF stem cell patent reversed
By The Business Journal of Milwaukee,
The Business Journal of Milwaukee
| 05. 03. 2010
The U.S. Patent and Trademark Office's Board of Appeals and Interference has reversed an earlier decision from the Patent Office's re-examination division that upheld the claims of one of the stem cell lines held by the Wisconsin Alumni Research Foundation.
The patent covers one of the three key stem cell lines that were challenged through re-examination proceedings initiated in October 2006 at the request of consumer watchdog groups New York City-based Public Patent Foundation and the Santa Monica, Calif.-based Foundation for Taxpayer and Consumer Rights, now called Consumer Watchdog.
The re-examination division upheld the validity of the patents in mid-2008, and the groups were allowed to challenge one of the patents in an appeal to the Board of Appeals and Interference.
The groups argue that the work done by University of Wisconsin researcher James Thomson to isolate stem cell lines was obvious in the light of previous scientific research, making his work unpatentable. The groups claimed the three WARF patents were "impeding scientific progress and driving vital stem cell research overseas."
The patent office rejected the arguments by the groups...
Related Articles
By Annalee Armstrong, BioSpace | 09.11.2024
Complex gene therapies are starting to hit the market but all have faced the same reality: a tepid reception from the healthcare system and a cloudy path to profitability.
It can take about a year for a patient to go...
By Staff, Kyodo News | 09.13.2024
Photo by Roméo A. on Unsplash
The Japanese government and people who were forced to undergo sterilization surgeries from the 1950s to the 1970s under a now-defunct eugenics protection law settled their lawsuits on Friday, following a recent ruling by...
By Sydney Lupkin and Asma Khalid, NPR | 08.15.2024
The White House unveiled the fruits of months of negotiations between the government and pharmaceutical companies: new, lower Medicare prices for 10 blockbuster drugs.
The discounts range from 79% for diabetes drug Januvia to 38% for blood cancer drug Imbruvica...
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...